DexCom Investment Research Report

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow large is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?6/10

  A

  Bottom line: the ceiling is high, but DexCom is mainly making a large, existing, and still-expanding pie larger, rather than creating a wholly new market from scratch. Its real incremental room lies in expanding indication and reimbursement boundaries, not in opening untouched territory.

  The demand base is an epidemiological long runway. The International Diabetes Federation (IDF) 2025 Diabetes Atlas estimates that about 589 million adults worldwide have diabetes, and expects that number to rise to about 853 million by 2050. In the United States, the CDC estimates that about 38.20 million Americans have diabetes (the report uses roughly 40.10 million, the same order of magnitude). This means CGM is not a short-cycle category that will be exhausted by novelty, but a long-duration business with the inertia of steadily rising prevalence.

  But it is important to separate “high ceiling” from “DexCom is creating the market.” Continuous glucose monitoring as a category has been developed jointly by Abbott’s Libre and DexCom for more than 10 years. Its core penetration has been in type 1 patients and severely insulin-dependent type 2 patients. DexCom’s real “larger pie” logic is pushing CGM outward from a “tool for heavy insulin users”: the American Diabetes Association (ADA), in its 2025 Standards of Care, has explicitly stated that CGM should be considered for adults with type 2 diabetes receiving non-insulin glucose-lowering therapy. Each outward step in reimbursement and indication boundaries expands the reachable population by another tier. This is the most realistic path for lifting its ceiling, and it is still, in essence, widening coverage within an existing category.

  The only piece with a “new market creation” flavor is Stelo, launched in August 2024 for non-insulin users and metabolic health consumers, and the first FDA-cleared OTC glucose biosensor in the United States. It does extend CGM from “prescription medical care” into a consumer health-management use case that did not previously exist in the same way. But the report is restrained here: whether Stelo can become a meaningful economic contributor remains unproven, and the report explicitly lists it as one of the watchpoints that could overturn the investment view. In other words, the option value of a new market exists, but it is far from having converted into reality.

  From a Baillie Gifford lens: the ceiling is enough to support a “long runway” narrative, but valuing it as a “brand-new blue ocean” would distort the picture. DexCom is competing for penetration in a long and broad existing lane that already has strong rivals on the field, not defining the rules in a blank space. That is also the fundamental reason the report gives “market ceiling” a positive assessment, but does not use it to lift valuation into the “disruptor” bracket.

  Jun 11, 2026
• QCan its revenue at least double over the next five years? Will growth be driven mainly by volume, price, or new businesses?5/10

  A

  Bottom line: revenue is unlikely to double over the next five years. By the company’s own numbers, even getting to slightly more than a doubling over five years would require maintaining roughly 15% compound growth throughout, while management’s official 2026 guidance is only about 11-13%. Structurally, the main driver is clearly volume, meaning installed sensors and repeat purchases; price is a net headwind; and new businesses (Stelo / non-insulin type 2) are still options.

  Start by pinning down the base and growth rate. DexCom reported 2025 revenue of $4.662 billion, up 16%, and the company’s 2026 revenue guidance is $5.16 billion to $5.25 billion, or about 11-13% growth. A rough calculation: starting from $4.662 billion, doubling in five years (by 2030) to about $9.3 billion requires about 14.8% annual compound growth without a break. At the guidance midpoint of about 12% compound growth, revenue would reach only about $8.2 billion in five years, roughly +76%, still short of doubling. So the honest answer is that “doubling in five years” requires growth to reaccelerate rather than slow, while current guidance points to moderate deceleration. A doubling is an optimistic scenario, not the base case.

  The sources of growth need to be separated into three buckets.

  First, volume is the absolute engine. The report is explicit: the primary driver of 2025 revenue growth was higher disposable sensor volume. The company added roughly 600,000-700,000 global net customers during the year (excluding Stelo), and its active customer base grew more than 20%, reaching about 3.5 million users at year-end. G7 and G7 15 Day have wear periods of 10 days and 15.5 days, respectively. As long as patients keep using them, consumables are purchased again and again. This is a classic “installed base plus repeat purchase” volume model, with high visibility on volume.

  Second, price is a headwind, not a tailwind. The report repeatedly stresses that DexCom does not have Coca-Cola-like pricing power, and 2025 growth was partly offset by “higher rebate eligibility and changes in channel mix.” Under the mass-market pressure from Abbott, whose CGM sales were about $7.6 billion in 2025 and clearly larger than DexCom, relying on price increases to contribute incremental growth is not realistic. It is also worth noting that G7 15 Day extends a single wear period from 10 days to 15.5 days, which actually lowers annual consumable usage per user. That is good for gross margin, but it adds resistance to “revenue per customer” growth.

  Third, new business is an option, not an engine that has already paid off. Stelo (OTC, non-insulin) and expansion into the broader type 2 population are directionally right, but the report lists “Stelo and the broader non-insulin type 2 market failing to form a meaningful economic contribution” as one of the signals that would overturn the investment view. That means they cannot yet support the arithmetic of a “doubling.”

  In sum, DexCom does not answer Baillie Gifford’s hard “five-year doubling” test especially well: directionally, this is healthy, volume-driven growth, but the growth band (about 11-13%) sits below the doubling line. It would need indication expansion, new-business scale-up, and renewed acceleration all to beat expectations at once to barely get there. That is the core reason the report scores “growth” conservatively and refuses to inflate the narrative.

  Jun 11, 2026
• QFive years from now, what will take over as the next growth engine? Does this “second curve” exist today?4/10

  A

  Bottom line: DexCom’s “second curve” does already exist today. Non-insulin type 2 / metabolic health users (with Stelo as the vehicle) plus the software and data ecosystem are candidates to take over from the main curve. But for now they are still early-stage options and have not yet produced meaningful economic contribution, so they look more like “clear direction, uncertain realization” than “the next growth engine already in hand.”

  First define the main curve: the bulk of current revenue is still prescription-grade CGM consumables for type 1 patients plus severely insulin-dependent type 2 patients, driven by G7 / G7 15 Day / G6 / Dexcom ONE+ and others, with 2025 revenue of $4.662 billion, up 16%. This curve remains healthy, but the report has already flagged signs of slowing: 2026 guidance growth falls to about 11-13%. So “who takes over five years from now” is a real question, not idle worry.

  There are two candidate second curves. Both are visible, but at different levels of maturity:

  First, mass adoption among non-insulin type 2 and metabolic health users, carried by Stelo. Launched in August 2024, it is the first FDA-cleared OTC glucose biosensor in the United States, targeting type 2 users who do not take insulin, people with prediabetes, and even metabolic health management users. Its strategic significance is large: it moves CGM outward from the narrow channel of “insurance reimbursement plus prescription” into the broader setting of consumer self-pay and retail access, with a potential population far larger than the current installed base. There is also clinical tailwind: in its 2025 Standards of Care, the ADA has recommended considering CGM for adults with type 2 diabetes receiving non-insulin therapy, which gives this curve guideline support. But the report is restrained: it lists “Stelo and the broader non-insulin type 2 market failing to form a meaningful economic contribution” as one of the watchpoints that could overturn the investment view, effectively acknowledging that this curve has not yet broken out.

  Second, software / data / ecosystem monetization. The company emphasizes that its products can connect to the “world’s largest connected CGM ecosystem,” and that it has used its “large database of continuous glucose data” to continuously optimize algorithms. The surrounding system includes Dexcom Clarity cloud reporting, smart insulin pen / insulin pump connectivity, and Dexcom Smart Basal, which received FDA clearance in 2025. Over the long term, extending from “selling sensors” to “selling data-driven metabolic management services” is a potential higher-margin second curve. But the report does not quantify it as a separate revenue engine; for now it is more of a moat component than a growth engine.

  The honest landing point (Baillie Gifford lens, with the focus on years 3-10): DexCom is not a company whose “second curve is nowhere to be seen.” Stelo and the data ecosystem both physically exist and point in the right direction, which is stronger than many growth stocks that have only a slide deck. But “existing” is not the same as “successfully taking over”: neither curve has yet proven that it can step in after the main curve slows and sustain overall growth. The right wording is therefore: the second curve has been planted, but it is not harvest season yet. Whether it pays off is the key variable that could move this investment from “qualified growth” toward a “fivefold possibility,” not an accomplished fact.

  Jun 11, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  Bottom line: DexCom’s core moat is a composite of regulatory credentials, product accuracy, ecosystem / switching costs, channel and reimbursement capability, and data algorithms, not a single barrier. Over the next three to five years it should be “overall wider, but mixed by dimension”: ecosystem, data, OTC and new indications are widening, while the “price moat” is steadily narrowing under Abbott’s mass-market pressure. This is a solid moat, but not an invincible one.

  Start by breaking down where the moat comes from. The report describes five layers, each with tangible evidence:

  First, regulation and clinical performance. Dexcom G7 15 Day received FDA clearance in 2025, extending wear to 15.5 days, and the company says its overall MARD is 8.0%, making it the most accurate FDA-approved CGM. Stelo is the first FDA-cleared OTC CGM in the United States. For medical devices, regulatory clearance and accuracy are not marketing language; they are the admission ticket into prescriptions, insurance coverage, and physician recommendation.

  Second, ecosystem and switching costs. G7 / G7 15 Day can connect with Dexcom Clarity, mobile devices, smartwatches, smart insulin pens, and insulin pumps. The company says it is connected to the “world’s largest connected CGM ecosystem,” and the sharing function allows up to 10 followers to receive data. For heavy insulin users, children, and caregivers, switching products is not just changing a sensor. It also means changing the app, historical data, alert logic, and care coordination. The switching cost is not as extreme as enterprise software, but it is far from zero.

  Third, data and algorithmic learning effects. The company explicitly says it has used its “large database of continuous glucose data” to continuously optimize algorithms. More installed devices produce more data, more data improves algorithms, and better algorithms strengthen physician trust. This creates a degree of positive feedback. It is not a strong network effect, but it is a real barrier.

  Fourth, channels and reimbursement. By the end of 2025, the 8 largest private payers in the United States had established coverage policies for the CGM category, and DexCom had also negotiated contract pricing. Medical devices often lose not on product, but on who educates physicians, who secures formulary access, and who helps patients get reimbursed. DexCom has built this route deeply.

  But the “divergence” inside the moat must be stated honestly. This is the report’s most restrained and most important judgment:

  The moat does not widen in one direction only. It is widening in ecosystem, data, and OTC; but it is narrowing in pricing power. Abbott’s CGM sales were about $7.6 billion in 2025, clearly larger than DexCom’s $4.662 billion, and Abbott’s public target is to take the Libre franchise to about $10 billion by 2028. Abbott is pursuing a scale + price + mass-coverage route; DexCom is pursuing accuracy + ecosystem + focus. The report states plainly that DexCom’s pricing power “exists, but is limited,” and in 2025 the company already acknowledged pricing headwinds from expanded rebate eligibility and channel-mix changes. In other words, DexCom sustains profitability through “better product plus higher adoption,” not through price increases. If its product / ecosystem advantages are partly replicated by lower-priced, broader-coverage competitors, this side of the moat will thin further.

  Replication threshold, which sets the floor for the moat: copying a sensor is not necessarily the hardest part. But replicating the full commercial system of “regulatory clearance + large-scale manufacturing + algorithms + clinical evidence + reimbursement contracts + physician education + ecosystem compatibility” takes years and massive capital. That is why the number of truly influential global players has remained small.

  Baillie Gifford lens: the moat strength deserves the report’s positive assessment, and its overall trend is expansionary enough to support “worth long-term research.” But the narrowing “price moat” is a real crack. It will not make DexCom immediately lose ground, but it can turn “volume growth with weakening unit economics” into a long-term shadow. That is why the report recognizes a solid moat, yet does not treat it as a “perfect business” with unlimited pricing power deserving a premium.

  Jun 11, 2026
• QIf the core business were disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?5/10

  A

  Bottom line: DexCom has an engineering DNA of continuous iteration and not resting on old products, as shown by the G6 -> G7 -> G7 15 Day -> Stelo product cadence. But it has not yet lived through the life-or-death test of having its core business truly disrupted and being forced into a wholesale reinvention. Its handling of mistakes and bad news is generally “transparent disclosure plus institutionalized correction,” which is adequate but not exceptional. In one sentence: it has the DNA for self-renewal, while its ability to truly “reinvent” itself remains untested under extreme conditions.

  Start with the “self-renewal” side. The evidence is concrete. DexCom is not a one-product-for-10-years company: it launched G7 in 2023, launched the OTC product Stelo for non-insulin users in August 2024, launched G7 15 Day at the end of 2025 (wear extended to 15.5 days, with a stated MARD of 8.0%), and in 2025 also received FDA clearance for Dexcom Smart Basal. G7 15 Day is especially worth noting because it extends a single wear period from 10 days to 15.5 days. That voluntarily reduces the annual usage of its own consumables, a tradeoff of short-term revenue for long-term user experience and gross margin. It shows a willingness to disrupt itself for product strength. The underlying support is algorithm optimization driven by a “large database of continuous glucose data.” This “data-algorithm-product” renewal loop is the source of DexCom’s ability to avoid being locked into one product generation.

  But “DNA for reinvention” deserves an honest discount. Baillie Gifford’s question asks whether the company can regrow itself if the core business is disrupted. On that point, DexCom is “untested,” not “proven.” It has never faced a situation where the supporting technology was replaced and the whole company had to transform. Its historical upgrades have been “making the product better inside the CGM main lane,” not a second founding across lanes. The report is alert to this uncertainty: it explicitly lists as a long-term risk that if a cheaper, more comfortable substitute with comparable or better accuracy appears, the profitability structure of today’s CGM leaders could be compressed. The right wording is therefore: it can update and iterate, but whether it can be reborn after a paradigm disruption is unanswered today.

  Now look at “how it handles mistakes and bad news,” a hard indicator of corporate honesty. DexCom’s performance is “transparent plus institutionalized”:

  First, bad news is put on the table and not avoided. Facing the FDA warning letter dated March 4, 2025 to its San Diego and Mesa facilities (the root cause involved a component design change in the G6/G7 sensor barrier layer that reduced accuracy), the company disclosed it in an 8-K and candidly acknowledged the warning letter, securities class actions, derivative lawsuits, and inventory reserves in the 10-K, without dressing it up. The report’s assessment is “candid acknowledgment.” This culture of not hiding landmines is a positive in handling bad news.

  Second, it corrects through systems rather than slogans. The company has enforced a clawback policy, and executive pay is tied to adjusted revenue, non-GAAP operating margin, and three-year relative TSR. In May 2026, ahead of Investor Day, it also announced governance enhancements: adding independent directors with medical technology and operating experience, strengthening specialized committee oversight, and emphasizing stricter operational discipline. The report gives this a “two-sided reading”: it shows the board responding actively to problems, but it also shows that governance upgrade was indeed needed. That refusal to package “remedial work” as a pure positive is exactly the restraint this question calls for.

  Landing point: DexCom is adequate at “admitting mistakes, disclosing them, and correcting through systems,” and it has an engineering DNA of continuous self-renewal. But whether it can reinvent itself after the core is disrupted remains untested. Add the ongoing new CEO transition and governance-strengthening phase of “repair and reacceleration,” and this dimension deserves a neutral assessment of “reasonable DNA, resilience still to be proven,” not an elevated claim of proven antifragility.

  Jun 11, 2026
• QDoes management, especially the founder, have a long-term view and deep alignment with the company? Is it willing to sacrifice current profit for the next five to ten years?4/10

  A

  Bottom line: DexCom is a professionally managed company, not a founder-controlled one. Its long-term orientation and incentive design are basically adequate, but “deep alignment with the company” deserves only a middle score: management and directors together own less than 1%, with no founder-style wealth commitment in the stock. It is willing to make some long-term tradeoffs, such as G7 15 Day reducing annual usage of its own consumables and retaining all earnings for reinvestment, but the new CEO’s full-cycle record is still short and discipline needs time to be verified.

  First, clarify whether this is a founder-aligned company, because that is the implied center of Baillie Gifford’s question. DexCom has long since stopped being a founder company: in September 2025, Kevin Sayer took medical leave, and Jake Leach became interim PEO, then formally became President and CEO in January 2026. Leach is not an outsider parachuted in. He had long been deeply involved in products and operations, so business continuity is protected. But “the public operating record is not yet long enough” is a real risk the report repeatedly emphasizes, and it is a governance negative. This question therefore cannot be answered with the romantic narrative of a founder sacrificing today for 10 years out. It has to be assessed as the discipline and alignment of a professional management team.

  On “alignment,” the report’s middle score is supported by hard data and should be presented honestly:

  First, ownership is low and does not amount to deep alignment. The entire board and executive team together hold about 1.0624 million shares, less than 1% of shares outstanding; current CEO Jacob Leach holds about 323,400 shares, also less than 1%. That is not misalignment, but it is far from “most of one’s net worth is in the stock.” At the current share price of about $77 and market cap of about $28 billion-$29.8 billion, total executive and director share value is only a little over $80 million, negligible relative to company size. This is the largest structural difference between DexCom and “founder-heavy” growth companies, and the root reason its “interest alignment” is discounted.

  Second, the incentive design is rational, but it relies on rules rather than personal fortune. The company has stock ownership guidelines: the CEO must hold 6 times annual salary, and other executives 3 times annual salary. Executives with more than three years of tenure were all compliant as of April 1, 2026; the company has also enforced a clawback policy. 2025 cash bonuses and PSUs were mainly tied to adjusted revenue, non-GAAP operating margin, and three-year relative TSR. This is more reasonable than simply chasing scale and steers toward “quality growth” rather than “growth for growth’s sake.” But note the distinction: these are rules requiring executives to hold stock, not the natural alignment of a founder who voluntarily has personal wealth concentrated in the shares.

  The evidence on “willingness to sacrifice current profit for the next five to ten years” is mixed:

  On the positive side, the company does not pay dividends and explicitly retains earnings for business expansion, while continuing to invest in manufacturing capacity (including the Ireland manufacturing site). That is a posture of sacrificing current distribution for long-term supply capability. G7 15 Day also extends the wear period and lowers annual usage of the company’s own consumables, a tradeoff that prioritizes long-term user value over short-term revenue.

  But the capital allocation record is “directionally right, mediocre in timing,” and should not be overstated: the company conducted large buybacks for three consecutive years from 2023-2025: $500 million / about 4.7 million shares in 2023, $750 million / about 10.4 million shares in 2024, and $500 million / about 7.7 million shares in 2025. A rough calculation puts the average repurchase price over the three years at about $106 / $72 / $65. 2025 was relatively rational, 2024 was close to today’s price, and 2023 was clearly at a more expensive level. The report’s judgment is that “the buyback direction was correct, but timing was not outstanding,” and that part of the buyback looked more like offsetting stock-compensation dilution than truly increasing intrinsic value per share.

  Baillie Gifford lens: DexCom’s management is “qualified professional managers plus a reasonable incentive system.” Its long-term orientation and honesty are acceptable, and it is willing to make some concessions for the long term. But it lacks founder-style deep alignment (ownership <1%), the new CEO’s cycle performance has not been verified, and the board is still “catching up on governance.” That is exactly why the report gives only a middle assessment to “management and capital allocation” and does not lift the growth narrative: alignment exists, but it is not extreme alignment.

  Jun 11, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not dependent on harming society or exploiting regulation?6/10

  A

  Bottom line: if DexCom disappeared tomorrow, heavy insulin users, children, and their caregivers would miss it considerably. For this group it is close to “daily necessity plus high switching costs.” But it is not “uniquely irreplaceable,” because Abbott’s Libre is a large and ready substitute. Sustainability is one of its strengths: CGM is a clinically positive tool that improves glucose management and reduces complications. It grows by “making patients healthier,” not by harming society, while the regulatory / payer system is generally moving toward “broader coverage and wider adoption,” not relying on gray areas.

  First answer “how much would customers miss it” by segmenting users and honestly separating “necessity” from “replaceability”:

  For severely insulin-dependent users, type 1 diabetes patients, children, and caregivers, DexCom is close to indispensable. It is not just a sensor; it is embedded in daily life. G7 / G7 15 Day connects with Dexcom Clarity cloud reporting, mobile devices, smartwatches, smart insulin pens, and insulin pumps, and the sharing function allows up to 10 followers to receive glucose data in real time. Parents monitoring children with diabetes and adult children remotely caring for elderly parents both rely on this data chain. Sudden disappearance would mean losing real-time alerts, historical trends, care coordination, and device compatibility. This “rupture in daily safety” is a real reason customers would miss it, and it is the source of the high switching costs emphasized by the report.

  But it must be stated honestly: it is not the only irreplaceable option. The CGM category has Abbott Libre, a large, more mass-market ready substitute. Abbott’s CGM sales were about $7.6 billion in 2025, clearly larger than DexCom’s $4.662 billion. So “DexCom disappearing” would create switching costs and inconvenience for individual users, but it would not mean “this kind of medical tool disappears from the world.” In other words, the people who would miss it are “loyal users,” not “the entire diabetes-management system.” That distinction determines that its indispensability is “high stickiness,” not “absolute monopoly.”

  Now address the double premise implied by the question: “indispensability” plus “social / regulatory sustainability”. This is where DexCom is genuinely strong:

  First, the growth model itself is socially positive and does not rely on harming others. The core value of CGM is helping diabetes patients manage glucose more precisely and reduce acute and long-term complication risks. The more it sells, in theory, the more it corresponds to better disease management, not antisocial monetization such as addiction, gambling, or environmental externalities. The clinical community supports this: the ADA’s 2025 Standards of Care recommend considering CGM for adults with type 2 diabetes receiving non-insulin therapy. The demand base is also a real clinical need: the IDF 2025 Diabetes Atlas estimates that about 589 million adults worldwide have diabetes, rising to about 853 million by 2050. This is a business where broader adoption should benefit society, which makes sustainability strong.

  Second, the regulatory and reimbursement direction is generally favorable, not based on loopholes. By the end of 2025, the 8 largest private payers in the United States had established coverage policies for the CGM category. The industry trend is that Medicare and commercial insurers are gradually relaxing coverage and pushing CGM from heavy users toward broader populations. DexCom’s growth is built on being recognized by the payment system and recommended by guidelines, not on regulatory arbitrage.

  But sustainability also has real constraints that must be marked clearly: DexCom is highly dependent on third-party payers. The report notes that company revenue depends heavily on distributors and third-party payers, and that multiple single customers account for more than 10% of revenue or accounts receivable. If payers raise eligibility thresholds, lower net prices, or change reimbursement pathways, growth quality would be affected. At the same time, the FDA warning letter in March 2025 is a reminder that, in regulated medical devices, “quality and compliance” are hard constraints on sustainability. Failure there can damage reputation and sales eligibility. So its sustainability is “directionally positive, but long constrained by payer bargaining power and regulatory compliance.”

  Baillie Gifford lens: DexCom scores solidly on the double test of “customer miss factor (strong for core users) plus social / regulatory sustainability (clinically positive, payer tailwind, not harmful to society).” This is one of the most defensible parts of the case for it as “a good business worth long-term study.” The only honest discount is the “indispensable = absolute” layer: Abbott’s existence means its moat is “high stickiness,” not “irreplaceability.”

  Jun 11, 2026
• QWhat are the unit economics of this business (gross margin, incremental returns)? Do they improve or deteriorate with scale? Where does the money it earns go?6/10

  A

  Bottom line: DexCom’s unit economics are “excellent but not extreme.” Gross margin is about 60%, operating margin is close to 20% and recovering, free cash flow has expanded materially to more than $1 billion, and scale effects are showing up. So for the past two to three years, the answer has leaned toward “more scale, more profitability.” But this is medical manufacturing with factories, yields, and replacement costs; gross margin is not as smooth as software subscription margin, and it faces pricing headwinds. The money it earns mainly goes to “capacity reinvestment plus buybacks.” There is no dividend; the capital allocation direction is right, but timing is ordinary.

  Start with the core unit economics, pinned down with primary data:

  Gross margin is about 60% and recovering. 2025 GAAP gross margin was about 60.1%, and operating margin recovered to 19.6%. In Q1 2026, GAAP gross margin recovered further to 62.9%, and GAAP operating margin was about 21.4%. The trajectory is “pressure first, then repair”: 2024 gross margin had fallen to 60.5% and operating margin to about 14.9%, mainly because inefficiencies from ensuring supply, configuration issues that hurt yields, and higher replacement costs weighed on results. In 2025-2026, margins rebounded as G7 15 Day contribution increased and manufacturing efficiency improved. This curve matters: it proves the 2024 pressure was not a permanent collapse, but also reminds investors that this is not a smooth upward curve. Manufacturing and replacement costs can truly bite into profit.

  Incremental returns improve with scale, and “larger means more profitable” has leaned true recently. This is the brightest part of the unit economics: 2025 operating cash flow was about $1.441 billion, capital expenditure about $364 million, leaving about $1.077 billion of free cash flow; Q1 2026 operating cash flow reached $525.6 million, with capital expenditure only $76.60 million. Compare the earlier period: 2021 free cash flow was only about $53.00 million (with very high capital expenditure that year). Based on this, the report judges that the ratio of FCF to net income was about 0.95 / 1.09 / 1.29 times in 2023-2025, meaning profits largely convert into cash and scale effects are appearing. In its 2026 investor materials, the company stated even more directly that it expects 2026 free cash flow to exceed $1 billion. This is quite different from companies that look like growth stocks but need more cash the larger they grow.

  But three ceilings on unit economics must be marked honestly, without polishing the growth story:

  First, this is manufacturing, not software. The cost structure includes direct labor, raw materials, assembly and testing, scrap, factory management, and facility costs. Free cash flow cannot be assessed by revenue alone; capacity ramp, replacement costs, inventory quality, and reimbursement discounts all matter. The report explicitly states that its unit economics are not as smooth as software subscriptions.

  Second, inventory and impairment pressure are real frictions. 2025 inventory impairment / reserve expense reached $92.80 million, materially higher than $53.50 million in 2024 and $16.60 million in 2023. Inventory rose from $543 million at the end of 2024 to $629 million at the end of 2025, then to $694 million in Q1 2026. Product transitions, demand forecasting, and quality control create real inventory and cost pressure. Investors cannot look only at revenue and ignore inventory.

  Third, gross-margin improvement comes from efficiency, not price increases. The report stresses that DexCom’s profit improvement path is yield improvement, product mix optimization, G7 15 Day contribution, freight, and manufacturing efficiency, not price increases. Under Abbott’s mass-market pressure and payer price pressure, price is a net headwind. This means the upside in unit economics is capped by the structural fact that it lacks strong pricing power.

  Where does the money it earns go? There is no dividend. The company explicitly retains earnings for business expansion: first, continued investment in manufacturing capacity (including the Ireland manufacturing site); second, large buybacks for three consecutive years (about $500 million / $750 million / $500 million in 2023/2024/2025, respectively). But the report judges the buybacks as “right direction, mediocre timing”: 2023 was clearly at a more expensive level, and part of the repurchase looked more like offsetting stock-compensation dilution than truly increasing intrinsic value per share.

  Baillie Gifford lens: unit economics are a fairly solid part of the DexCom case. It has real profits, real cash flow, and real scale effects, deserving the report’s positive assessment. This is also the physical advantage that separates it from “cash-burning growth stocks.” But it is “excellent medical manufacturing,” not “extreme software leverage.” Gross margin is constrained by yield, replacement, and pricing frictions, while upside is capped by lack of strong pricing power. So it is “more scale, more profitability, but steady rather than explosive.”

  Jun 11, 2026
• QWhat conditions must all be true for it to rise fivefold in ten years? Are those conditions realistic? What expectations does today’s share price imply?3/10

  A

  Bottom line: getting DexCom to a fivefold gain in ten years is a high bar that requires several optimistic things to be true at the same time. Buying at about $77 today, with a market cap of about $28 billion-$29.8 billion and a P/E of about 31 times, the share price already implies “sustained excellence,” not “obvious undervaluation.” A fivefold outcome requires both fundamentals and valuation to hold up, and the realistic probability is not high. This is the core arithmetic behind the report’s “Watch” rather than “Buy” rating and its emphasis on insufficient margin of safety.

  First, break “fivefold in ten years” into the chain of conditions that must hold simultaneously (Baillie Gifford’s focus is years 3-10, and each point is checked against reality):

  Condition 1: revenue rises about fivefold over ten years, with compound growth of about 17-18% throughout. Starting from 2025 revenue of $4.662 billion, a fivefold revenue outcome in ten years means about $23 billion of revenue. Reality: the company’s 2026 guidance is only about 11-13% growth, pointing to moderate deceleration rather than acceleration. To reach a long-term compound rate of 17-18%, non-insulin type 2 / OTC (Stelo) / international markets would all have to scale in sequence and push growth back up. Yet the report specifically lists “Stelo and the broader type 2 market failing to form a meaningful economic contribution” as a signal that would overturn the thesis. This is the tightest link in the fivefold case, and it has not paid off today.

  Condition 2: margins keep expanding, with profit growing faster than revenue. Revenue rising fivefold is not enough by itself; gross margin / operating margin must keep recovering and amplify earnings. 2026 guidance for non-GAAP operating margin is about 22-23%, leaving some room for improvement, but upside is capped by three frictions: no strong pricing power, Abbott price pressure, and manufacturing yield / replacement costs.

  Condition 3: valuation does not contract, or at least does not contract materially. This is the hidden killer in the fivefold case. The current P/E of about 31 times is not cheap. If, ten years from now, the market reprices DexCom to ordinary medical-device levels (for example, Abbott at about 23 times and Medtronic at about 21 times), then even if profit really does multiply several times, valuation compression would eat deeply into the stock’s path to fivefold. In other words, the fivefold case requires “high growth plus high valuation” to persist together for ten years. That is a demanding assumption for a company whose growth is slowing and that faces a large-scale competitor.

  Condition 4: no major regulatory or competitive accident. The FDA warning letter from March 2025 must be fully closed without escalation; Abbott (2025 CGM about $7.6 billion, with a 2028 Libre target of about $10 billion) must not push the industry into low-price commoditization. If either deteriorates, the fivefold narrative breaks.

  Are these conditions realistic? Each one, individually, is not absurd. But the joint probability that all of them hold at the same time, and for ten years, is not high. That is the report’s judgment: DexCom is a candidate for a quality-driven long-term position, but it is not a cheap asset with obvious margin of safety and an inevitable fivefold outcome.

  What does today’s share price imply? This is the core of the question, and the report’s arithmetic is clear: buying at about $77 and about 31 times P/E means the market has already priced in “continued mid-to-high single-digit to low-teens growth for many years, continued margin repair, and no major regulatory / competitive accident.” The report’s three valuation methods cross-check to conservative intrinsic value of about $47-$55, fair value of about $65-$75, and optimistic value of about $90-$100. The current price is already at the upper end of the fair range and clearly above conservative value. When the report was written at about $71.9, it already judged the stock to be “mid-to-lower within neutral value, and clearly at a premium to conservative value.” Now that the share price has risen to about $77, margin of safety can only be thinner, not thicker. That means today’s buyer increasingly depends on the optimistic scenario playing out, rather than earning from valuation buffer. The report’s ideal buy range is $50-$60, and the current price is meaningfully above it.

  Baillie Gifford lens: honestly, DexCom does not answer the “fivefold in ten years” question well. The fundamentals are good, but growth is slowing, valuation is not cheap, and a fivefold outcome requires multiple optimistic conditions to be true simultaneously. It looks more like a high-quality long-term stock likely to beat Treasuries over ten years, with a neutral-scenario high-single-digit annualized return, than a mispriced growth blockbuster destined to go fivefold. Today’s price does not imply “the market missed it”; it implies “the market has already granted the premium a good company deserves.” That is the fundamental reason the report refuses to lift the growth narrative and sticks with “Watch.”

  Jun 11, 2026
• QWhy has the market not realized all of this yet? Is it because the market does not understand it, looks down on it, or cannot look far enough? What will become the “narrative inflection point”?3/10

  A

  Bottom line: for DexCom, the premise that “the market has not realized it” is not very valid. This is not an ignored, misunderstood, or disrespected stock; it is a well-covered star growth stock with a full premium (about 31 times P/E). The real perception gap is not “the market undervalues it,” but “whether the market overbelieves in its ability to stay excellent and underestimates the triple headwinds of price, quality, and competition.” So the narrative inflection point is more likely to be a negative de-rating (FDA, share, gross margin failure) than a positive value re-rating.

  First correct the implied assumption in the question. Baillie Gifford’s original question, “why has the market not realized it yet (doesn’t understand / looks down / cannot look far enough),” is usually used to identify cheap, wrongly punished good companies. DexCom is not in that category, and valuation itself is the evidence: the current P/E is about 31 times, market cap is about $28 billion-$29.8 billion, and the stock has traded in a wide range of about $54 to $90 over the past year, with dense sell-side coverage and substantial institutional ownership. The report’s cross-sectional comparison confirms this: DexCom is more expensive than large diversified device companies such as Abbott (about 23 times) and Medtronic (about 21 times), and only slightly cheaper than Insulet, another high-growth diabetes-device company. The report’s judgment is direct: current valuation reflects “the premium a good company should have,” not “the market clearly underestimates it.” In other words, the market understands it and respects it. It has not missed it; it has priced it.

  So where is the real “perception gap”? Not in “market undervaluation,” but in “different interpretations of the same facts.” This is the most valuable part of the report’s breakdown:

  The bull narrative (why the market mainstream gives it a premium): diabetes prevalence is rising long term (the IDF 2025 edition estimates about 589 million globally and about 853 million by 2050); CGM’s clinical applicability is expanding (the ADA 2025 Standards recommend use for non-insulin type 2); disposable sensors drive recurring revenue (about 600,000-700,000 net new customers in 2025, with active users above 3.5 million); and free cash flow has exceeded $1 billion.

  The bear / cautious narrative (the side the report takes): DexCom lacks traditional strong pricing power. Its advantage is “better product plus better ecosystem,” and if lower-priced, broader-coverage competitors partly replicate those, the premium could be repriced quickly. Add the unresolved FDA warning letter, the 2025 inventory reserve rising to $92.80 million, and slowing U.S. growth, and the stock could enter a long period of “high quality but low return” even without collapsing. The report’s conclusion is that the market may be too optimistic and may underestimate the double test of pricing and quality execution. That is the real disagreement, which is the opposite of a “missed cheap stock.”

  What could become the “narrative inflection point” (the implied follow-up in this question, which needs both directions):

  Negative inflection points, which are more likely and would trigger de-rating: the report has identified 5 sell signals that can be treated as an inflection-point list: 1. the FDA warning letter escalates into substantive restrictions on production / import / sales or a recall; 2. GAAP gross margin falls back below 60% and stays there, proving G7 15 Day repair failed; 3. U.S. revenue growth lags the industry or rivals materially for several consecutive quarters, showing share loss to Abbott; 4. Stelo and the broader type 2 market never form meaningful economic contribution; 5. large buybacks fail to increase intrinsic value per share. If any one of these is confirmed, the market will drag it from “growth premium” toward “ordinary device valuation.”

  Positive inflection points, if realized, could move it up another level: non-insulin type 2 / OTC scale-up is confirmed by data, gross margin continues to recover toward the high 60% range, the FDA issue is cleanly closed, and the new CEO builds a credible capital-allocation record. But these are more about delivering on existing optimistic expectations and supporting the current premium, rather than creating new room for a “value re-rating.”

  Baillie Gifford lens: DexCom is not a “dust-covered jewel the market does not understand.” It is a high-quality growth stock that the market understands clearly and has already awarded a full premium. The perception gap is not whether valuation is high or low, but whether the market is too optimistic about the triple headwinds of pricing-power erosion, quality execution, and competitive commoditization. That means the next inflection point is more likely to be a negative expectation reset than positive value discovery. For the same reason, the report does not use “the market has not realized it” as a Buy argument. It says plainly: today’s price already includes the optimistic narrative, margin of safety is insufficient, and the right stance is to “Watch” and wait for better odds.

  Jun 11, 2026